STOP-CA (Statins TO Prevent the Cardiotoxicity From Anthracyclines)

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 300 participants.

Also called NCT02943590

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 300 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02943590
Other papers using this trial's data
  • Atorvastatin and Aortic Stiffness During Anthracycline-Based Chemotherapy: A Secondary Analysis of a Randomized Clinical Trial JAMA cardiology, 2026-01-01 DOI, PubMed 41205202, PMC12596745 Not in the PMC Open Access subset.
  • Atorvastatin and left atrial function during anthracycline-based chemotherapy Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance, 2025 DOI, PubMed 40876541, PMC12713124 In the PMC Open Access subset under CC BY-NC-ND.
  • Atorvastatin and left ventricular strain during anthracycline-based chemotherapy International journal of cardiology, 2026-07-01 DOI, PubMed 41875954
  • Atorvastatin for Anthracycline-Associated Cardiac Dysfunction: The STOP-CA Randomized Clinical Trial JAMA, 2023-08-08 DOI, PubMed 37552303, PMC10410476 Not in the PMC Open Access subset.
  • Effect of atorvastatin versus placebo on efficacy in patients with diffuse large B-cell lymphoma receiving R-CHOP Leukemia & lymphoma, 2024-06 DOI, PubMed 38380861, PMC11342236 In the PMC Open Access subset under a licence that is not Creative Commons.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02943590. Randomized; double masking; primary purpose treatment. Start 2017-01-13 (actual); primary completion 2022-09-16 (actual). Results posted on 2023-12-18.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
STOP-CA (Statins TO Prevent the Cardiotoxicity From Anthracyclines)
Condition
Heart Failure
Intervention (Drug)
Placebo
Intervention (Drug)
Atorvastatin
Lead sponsor
Massachusetts General Hospital (class: other)
Collaborator
Dana-Farber Cancer Institute (class: other)
Collaborator
Brigham and Women's Hospital (class: other)

Record details

Record id
cardio:ct-nct02943590
Content hash
592807cd6c27bc7ee7b472a5c18b3056eec730ce0b9f7c1a36e16adbc3cecdd0